间质植入近距离照射治疗前列腺癌

王宇

间质植入近距离照射治疗前列腺癌

王宇

文章导航 > 国际放射医学核医学杂志 > 2001, 25 > 5: (233-236)

引用本文:

Citation:

间质植入近距离照射治疗前列腺癌

王宇

210009 江苏南京, 南京东南大学医学院核医学技术研究所

作者简介: 王宇(1973-),女,黑龙江齐齐哈尔人,南京东南大学医学院硕士研究生。;

基金项目:
江苏省科技厅应用基础资助项目(BJ2000004)
中图分类号: R817.5

Interstitial implantation brachytherapy for the treatment of prostate carcinoma

WANG Yu

Nuclear Medicine technical institute, Medical College of South East University, Jiangsu Nanjing 210009, China
CLC number: R817.5

摘要: 简述间质植入近距离照射治疗前列腺癌的概况及操作方法,介绍所用核素的特点和选择,评价该疗法的适应证、临床疗效、并发症及与其他疗法的比较。
- 前列腺癌 /
- 近距离照射治疗 /
- 放射性核素籽源
Abstract: It briefly describes the current states and operative procedure of interstitial implantation brachytherapy treatment of prostate carcinoma. The characteristics and selection of employed radioisotopes are introduced.It also evaluates the indications,results and complications of this technique,and compar with the other therapies.
- prostate carcinoma /
- brachytherapy /
- radioisotope seeds
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Stone N N, Ramin SA, Wesson MF, et al. Laparoscopic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed prostate[J]. J Urol, 1995, 153:1555-1560.
[2]	Blasko JC, Grimm PD, Ashley R, et al. Palladium-103 brachytherapy for prostate carcinoma[J]. Int J Radiat Oncol Biol Phys, 2000, 46(4):839-850.
[3]	Sylvester J, Blasko JC, Grimm P, et al. Interstitial implantation techniques in prostate cancer[J]. J Surg Oncol, 1997, 66:65-75.
[4]	Ling CC. Permanent implants using Au-198, Pd-103 and I-125:Radiobioligical considerations based on the linear quadratic model[J]. Int J Radiat Oncol Biol Phys, 1992, 23:81-87.
[5]	Cha CM, Potters L, Ashley R, et al. Isotope selection for patients undergoing prostate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2):391-395.
[6]	Wuu CS, Ennis RD, Schiff PB, et al. Dosimetric and volumetric criteria for selecting a source activity and a source type (¹²⁵I or ¹⁰³Pd) in the presence of irregular seed placement in permanent prostate implans[J]. Int J Radiat Oncol Biol Phys, 2000, 47(3):815-820.
[7]	Blasko JC, Grimm PD, Ragde H, et al. Brachytherapy and organ preservation in the management of carcinoma of the prostate[J]. Semin Radiat Oncol, 1993, 3:240-249.
[8]	Wallner K, Roy J, Harrion L, et al. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 1995, 32:465-471.
[9]	Anderson LL. Spacing nomograph for interstitial implants of I-125 seeds[J]. Med Phys, 1976, 3:48-51.
[10]	Anderson LL, Moni JV, Harrion LB, et al. A nomograph for permanent implants of palladium-103 seeds[J]. Int J Radiat Oncol Biol Phys, 1993, 27:129-135.
[11]	Yu Y, Waterman FM, Suntharalingam N, et al. Limitations of the minimum peripheral dose as a parameter for dose specification in permanent ¹²⁵I prostate implants[J]. Int J Radiat Oncol Biol Phys, 1996, 34:717-725.
[12]	Anon. Consensus statement:guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel[J].Int J Radat Oncol Biol Phys, 1997, 37(5):1035-1041.
[13]	Prestidge BR, Hoak DC, Grimm PD, et al. Post-treatment biopsy results following interstitial brachytherapy in early stage prostate cancer[J]. Int J Radiat Oncol Biol Phys, 1997, 37:31-39.
[14]	Ragde H, Korb LJ, Elgamal AA, et al. Modern Prostate Brachytherapy:prostate bpecific antigen results in 219 patients with up to 12 years of observed follow-up[J].Cancer, 2000, 89(1):135-141.
[15]	Blasko JC. Brachytherapy[J]. Urology, 2000, 55:306-308.
[16]	Brachman DG, Thomas T, Hilbe J, et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients:results from a single practice[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):111-117.
[17]	D'Amico AV, Whittington R, Malkowicz SB, et al.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer[J]. JAMA, 1998, 280(11):969-974.
[18]	Nori D, Mori J. Current issues in techniques of prostate brachytherapy[J]. Semin Surg Oncol, 1997, 13:444-453.
[19]	Arterbery VE, Frazier A, Dalmia P, et al. Quality of life after permanent prostate implant[J]. Semin Surg Oncol, 1997, 13:461-464.
[20]	Baird MC, Holt RW, Selby TL, et al. Improvement of transperineal implant dosimetry by intraoperative cystoscopic confirmation of prostate anatomy[J]. J Urol, 2000, 164:406-416.
[21]	Whittington R, Broderick GA, Arger P, et al. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guide interstitial therapy for localized carcinoma of the prostate[J]. Int J Radiat Oncol Biol Phys, 1999, 44(5):1107-1110.

[1]	秦岚 . 前列腺癌近距离放射治疗的进展. 国际放射医学核医学杂志, 2005, 29(4): 159-161.
[2]	王俊杰 . 放射性粒子近距离治疗前列腺癌:临床篇. 国际放射医学核医学杂志, 2002, 26(3): 101-104.
[3]	廖安燕 , 王俊杰 . 持续低剂量率照射治疗前列腺癌的生物学效应. 国际放射医学核医学杂志, 2005, 29(4): 190-192,封三.
[4]	陈立波 . 钠/碘同向转运体与放射性碘治疗. 国际放射医学核医学杂志, 2001, 25(6): 258-261.
[5]	陆汉魁 , 林祥通 , 刘家慧 , 林汉 . 乳腺癌和前列腺癌的类固醇受体显像研究现状. 国际放射医学核医学杂志, 1996, 20(3): 106-109.
[6]	郝玉美 , 贺欣 , 宋娜玲 . 前列腺癌干细胞分离方法研究进展. 国际放射医学核医学杂志, 2013, 37(5): 296-300. doi: 10.3760/cma.j.issn.1673-4114.2013.05.011
[7]	许杨 . 前列腺特异性抗原及其临床应用. 国际放射医学核医学杂志, 2000, 24(5): 201-205.
[8]	马蕊 , 张良安 . 高剂量率近距离放射治疗前列腺癌. 国际放射医学核医学杂志, 2007, 31(3): 191-193.
[9]	熊正平 , 张阳德 , 黄芳 , 梁赵玉 , 杨树仁 . 前列腺癌放射治疗进展. 国际放射医学核医学杂志, 2007, 31(1): 58-60.
[10]	王济东 , 王俊杰 . 胰腺癌组织间近距离放射治疗的研究进展. 国际放射医学核医学杂志, 2006, 30(3): 182-184.